Kanker-actueel Velcade - Bortezomib shows promising therapeutic value in patients with relapsed mantle-cell lymphoma and also encouraging results in patients with recurrent B-cell lymphomas other. This emerges from a phase II study in 60

Startpagina

Contact | Disclaimer | Sitehulp

Sitemap | Video's

Patiëntenervaringen | Lotgenotencontact

Forum |

Onze Sponsors

Cancer Types

Regular

Complementary

Coaching

Donations

Questions

Cancer News

Addresses

Prevention

Recipes

Artikelen

Lymphoma. Hodgkin's disease and Non-Hodgkin's lymphoma. (General and supplementary)

Standard treatment for Hodgkin's disease and non-Hodgkin and cure many different opportunities.

Overall: chance of getting half and / or other form of cancer after successful treatment and survival of non-Hodgkin was significantly higher compared to people who never had cancer.

Radiotherapy - Radiotherapy in Non-Hodgkin: Non-Hodgkin's patients - younger than 30 years - which have become irradiated for lymphoma - non-Hodgkin's disease and have survived around 40% greater chance of getting breast cancer later. Update November 27, 2010

Chemo and effect in lymphoma: Patients with Hodgkin's disease would benefit from new chemomix - with increased dose BEACOPP - and would not benefit from additional radiotherapy radiotherapy after chemotherapy according to two long-term randomized trials. Update November 27, 2010

Chemotherapy and radiotherapy: 2x 2x irradiation after chemotherapy for lymphoma - Hodgkin lymphoma shows similar results on disease-free and recurrence rates as 4x irradiation, but obviously with much less chance of serious side effects and later complications such as other cancers. Thus long-term randomized phase III study. Article posted August 15, 2010

Chemo and radiation for lymphoma - Non-Hodgkin and Hodgkin's disease - gives high risk for future new forms of cancer. In young women, 136 times greater risk of breast cancer such reports in the Lancet study says. Update November 27, 2010

Chemo and effect in lymphoma, the chemotherapy combination of doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (ACVBP) provides significantly better results, longer survival time, the chemotherapy combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radiotherapy for treating localized aggressive lymphoma

Chemo and effect in mantle-cell lymphoma: An approach first a single dose of Rituximab plus cyclophosphamide, vincristine, doxorubicin and dexamethasone (hyper-CVAD) followed by Rituximab plus high-dose methotrexate, cytarabine, high durable remissions observed in new patients with an aggressive form of mantle cell lymphoma. But the side effects and disease-related mortality was high with this approach.

Chemo and effect in lymphoma: Rituximab - Mabthera added to CHOP therapy for lymphoma - B-cell lymphoma shows superior results in randomized phase III study. Update November 27, 2010

Chemo for lymphoma: A combination treatment of fludarabine, cyclophosphamide, and rituximab shows significant better results in time to disease progression and survival in Hodgkin and non-CLL = chronic lymphocytic leukemia. Article posted May 26, 2006

Diagnosis of lymphoma: Lymphoma can now be better defined by new diagnostic method.

Hepatitis B virus infection indicates increased risk of lymphoma, said large population. Article posted August 15, 2010

MabThera - Rituximab - Rituxan seems best approach for lymph node cancer: Some studies put together

Nipent gives promising results in lymphoma - Non-Hodgkin's and leukemia

Nipent appears to be effective in various types of blood cancers including hairy cell leukemia and chronic lymphocytic leukemia, a form of non-Hodgkin

Overview Study in Lymphoma: A survey of 37 case studies with multiple cancers in a study group of 810 patients with lymphoma and how certain formal approach worked or not and gives good insight into the different types of lymphoma involving other organs also by cancer were affected, with or without other forms of primary cancer or metastases. Update November 27, 2010

Prozac and lymphoma: Prozac causes rapid laboratory suicide - apoptosis - in Burkitt's lymphoma, an aggressive form of lymphoma, mainly occurring in AIDS patients.

FDA has serious doubts presented Phase III study results for Pixantrone lymfklierkankerpatienten - non-Hodgkin's where previously failed chemotherapy. Article updated February 9, 2010

PDT - photodynamic therapy lymfklierkankercellen kills T cells and leave intact.

Stem cell transplantation for lymphoma: stem cell transplantation (allogeneic) in relapsed non-Hodgkin gives 43% five-year disease-free survival and overall 5 year survival 48%, from Phase II study of 44 patients with relapsed aggressive non-Hodgkin. This new study confirms earlier studies from 2002 and 2005 with same positive results. Update November 27, 2010

Velcade - Bortezomib also shows significant value in forms of non-Hodgkin lymphoma mantle namely - MLC and indolent non-Hodgkin's, said phase II study.

Velcade - Bortezomib shows promising therapeutic value in patients with relapsed mantle-cell lymphoma and also encouraging results in patients with recurrent B-cell lymphomas other. This emerges from a phase II study in 60 patients divided into two groups: group A with mantle cell lymphoma patients and group B patients with other B-cell lymphomas, including non-Hodgkin focculaire, Waldenstrom etc.

Food and nutrients to lymphoma - Non-Hodgkin: Preventive effect of food and nutrients, Who daily fruit and vegetable food, while additional specific antixidanten take, namely lutein and zeaxanthin and zinc reduce the risk of lymph gland cancer - non-Hodgkin significant.

Food and voedinngstoffen with lymphoma - Non-Hodgkin: Preventive effect of food and nutrients: Women sufficient daily amounts of fruits and vegetables reduce the risk of lymph gland cancer - non-Hodgkin. This is evident from the large Nurses' Health Study, which very often is noted in scientific circles.

Sunlight - (vitamin D) protects against many cancers (25% to 40%), including lymklierkanker (non-Hodgkin's) and even non-melanoma skin cancers.

Brentuximab Vedotin (SGN-35) shows successful approach for advanced and recurrent lymphoma, non-Hodgkin lymphoma with positive CD30 expression. According to the Volkskrant has caused a run on this drug, creating a shortage. Article posted June 7, 2011

Ve lymphoma patients: Mv. Bruins opted for a wait and see policy, so no chemo, etc., but the Moerman / Houtsmuller diet and certain nutritional supplementation and received its non-Hodgkin's completely mastered and has been cancer-free.

Experience Story lymphoma - Non-Hodgkin: Dutch wife Joan Holstein refuses chemo for her non-Hodgkin and heals anyway mistletoe injections and healthy lifestyles. Article updated June 7, 2011

Ve lymphoma patients: Marja is after and during chemotherapy to address vegetarian diet (Houtsmuller Diet), certain nutritional supplements and some lifestyle's lymphoma non-Hodgkin's high-grade stage IV under control and reached by physicians total remission and feels well and happy. Read her moving and fighting experience story that hopefully an incentive for others.

Irradiation-radiotherapy plus Zevalin and Bexxar immunotherapies with a.o. shows excellent approach for certain forms of cancer, including non-Hodgkin's lymfklier. Recent study added. Article update 11 January 2012

Irradiation-Radio therapy in non-Hodgkin's lymphoma and labeled with monoclonal antibodies gives significantly longer time of survival, even if previous treatments failed.

Irradiation-Radio therapy in non-Hodgkin's lymphoma stage III and IV low-grade gives remarkable longer period to relapse and significantly more total remissions (CR 60% average 42 months long), in spite of one or more chemotherapy that has already been done, thus randomized phase III study in multiple hospitals in Netherlands and Belgium.

Bexxar, a monoclonal means tagged with a radioactive component allows for remarkably good effects in aggressive form of recurring non-Hodgkin 's.

BiovaxID immunotherapy: a vaccination with significantly longer disease-free time at lymfklier gives cancer (non-Hodgkin-FL) seen from phase III study. Article update 11 January 2011

Cancer Immunotherapies to BiovaxID (TM), lymfklier: a Vaccination-immunotherapies in non-Hodgkin gives good results from phase I and II and phase III trials.

Cancer Immunotherapies with lymfklier: Non-Hodgkin and vaccination with BiovaxID is successful and promising approach.

Pixantrone makes for remarkably good effects in aggressive form of cancer-non-Hodgkin's lymfklier, where chemo failed. European Commission is considering official approval. Article update 22 February 2012

Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease

Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.

Recent articles in left column more or less in alphabetical order classified

Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.

If you want to support us you can do so through a donation: See registration OPS

Velcade - Bortezomib shows promising therapeutic value in patients with relapsed mantle-cell lymphoma and also encouraging results in patients with recurrent B-cell lymphomas other. This emerges from a phase II study in 60 patients divided into two groups: group A with mantle cell lymphoma patients and group B patients with other B-cell lymphomas, including non-Hodgkin focculaire, Waldenstrom etc.

Velcade - Bortezomib shows promising therapeutic value in patients with relapsed mantle-cell lymphoma and also encouraging results in patients with recurrent B-cell lymphomas other. This emerges from a phase II study in 60 patients divided into two groups: group A with mantle cell lymphoma patients and group B patients with other B-cell lymphomas, including non-Hodgkin focculaire, Waldenstrom etc.